Functional polymorphisms and methotrexate treatment outcome in recent-onset rheumatoid arthritis

Pharmacogenomics

Volumn 11, Issue 2, 2010, Pages 163-175

  Kooloos, Wouter M ^a   Wessels, Judith Am ^a   Van Der Straaten, Tahar ^a   Allaart, Cornelia F ^a   Huizinga, Tom Wj ^a   Guchelaar, Henk Jan ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Functionality; Methotrexate; Pharmacogenetics; Replication study; Rheumatoid arthritis; SNP

Indexed keywords

DIHYDROFOLATE REDUCTASE; FOLIC ACID; HLA G ANTIGEN; INOSINATE DEHYDROGENASE; INOSINE PHOSPHATE; INOSINE TRIPHOSPHATE; METHOTREXATE; MULTIDRUG RESISTANCE PROTEIN 1; TOLL LIKE RECEPTOR 4; TRANSFORMING GROWTH FACTOR BETA1;

ARTICLE; CONSTIPATION; CONTROLLED STUDY; DIARRHEA; DISEASE ACTIVITY; DRUG DOSE INCREASE; DRUG EFFICACY; ETHNICITY; GASTROINTESTINAL DISEASE; GENE FREQUENCY; GENE LOCUS; GENE REPLICATION; GENETIC ANALYSIS; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENETIC VARIABILITY; GENOTYPE; HOMOZYGOSITY; HUMAN; IMMUNOPATHOGENESIS; LEUKOPENIA; MAJOR CLINICAL STUDY; MUCOSAL DISEASE; NAUSEA; OUTCOME ASSESSMENT; PHARMACOGENETICS; PNEUMONIA; PYROSEQUENCING; RHEUMATOID ARTHRITIS; SINGLE NUCLEOTIDE POLYMORPHISM; SKIN DISEASE; VOMITING;

AGE OF ONSET; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; COHORT STUDIES; DATA INTERPRETATION, STATISTICAL; DISEASE PROGRESSION; DNA; ENDPOINT DETERMINATION; GENOTYPE; HUMANS; METHOTREXATE; ODDS RATIO; PHARMACOGENETICS; POLYMORPHISM, GENETIC; POLYMORPHISM, SINGLE NUCLEOTIDE;

EID: 77949623072     PISSN: 14622416     EISSN: 17448042     Source Type: Journal    
DOI: 10.2217/pgs.09.139     Document Type: Article

References (67)

1. Emery P, Breedveld FC, Dougados M, Kalden JR, Schiff MH, Smolen JS: Early referral recommendation for newly diagnosed rheumatoid arthritis: evidence based development of a clinical guide. Ann. Rheum. Dis. 61(4), 290-297 (2002).
2. Smolen JS, Aletaha D, Machold KP: Therapeutic strategies in early rheumatoid arthritis. Best. Pract. Res. Clin. Rheumatol. 19(1), 163-177 (2005).
3. Cronstein BN: Low-dose methotrexate: a mainstay in the treatment of rheumatoid arthritis. Pharmacol. Rev. 57(2), 163-172 (2005).
4. Aletaha D, Smolen JS: The rheumatoid arthritis patient in the clinic: comparing more than 1,300 consecutive DMARD courses. Rheumatology (Oxford) 41(12), 1367-1374 (2002).
5. Klareskog L, van der Heijde D, de Jager JP, et al.: Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised controlled trial. Lancet 363(9410), 675-681 (2004).
6. Mottonen T, Hannonen P, Leirisalo-Repo M et al.; FIN-RACo Trial Group: Comparison of combination therapy with single-drug therapy in early rheumatoid arthritis: a randomised trial. Lancet 353(9164), 1568-1573 (1999).
7. Eichelbaum M, Ingelman-Sundberg M, Evans WE: Pharmacogenomics and individualized drug therapy. Annu. Rev. Med. 57, 119-137 (2005).
8. Dervieux T, Furst D, Lein DO et al.: Polyglutamation of methotrexate with common polymorphisms in reduced folate carrier, aminoimidazole carboxamide ribonucleotide transformylase, and thymidylate synthase are associated with methotrexate effects in rheumatoid arthritis. Arthritis Rheum. 50(9), 2766-2774 (2004).
9. Wessels JA, Kooloos WM, De Jonge R. et al.: Relationship between genetic variants in the adenosine pathway and outcome of methotrexate treatment in patients with recent-onset rheumatoid arthritis. Arthritis Rheum. 54(9), 2830-2839 (2006).
10. Evans WE, Relling MV: Pharmacogenomics: translating functional genomics into rational therapeutics. Science 286(5439), 487-491 (1999).
11. Hattersley AT, McCarthy MI: What makes a good genetic association study? Lancet 366(9493), 1315-1323 (2005).
12. Wessels JA, van der Kooij SM, le Cessie S. et al.: A clinical pharmacogenetic model to predict the effcacy of methotrexate monotherapy in recent-onset rheumatoid arthritis. Arthritis Rheum. 56(6), 1765-1775 (2007).
13. Hider SL, Bruce IN, Thomson W: The pharmacogenetics of methotrexate. Rheumatology (Oxford) 46(10), 1520-1524 (2007).
14. Wesoly J, Wessels JA, Guchelaar HJ, Huizinga TW: Genetic markers of treatment response in rheumatoid arthritis. Curr. Rheumatol. Rep. 8(5), 369-377 (2006).
15. Colhoun HM, McKeigue PM, Davey SG: Problems of reporting genetic associations with complex outcomes. Lancet 361(9360), 865-872 (2003).
16. Rebbeck TR, Spitz M, Wu X: Assessing the function of genetic variants in candidate gene association studies. Nat. Rev. Genet. 5(8), 589-597 (2004).
17. Arnett FC, Edworthy SM, Bloch DA et al.: The American Rheumatism Association 1987 revised criteria for the classifcation of rheumatoid arthritis. Arthritis Rheum. 31, 315-324 (1988).
18. Goekoop-Ruiterman Y P, de Vries-Bouwstra JK, Allaart CF et al.: Clinical and radiographic outcomes of four different treatment strategies in patients with early rheumatoid arthritis (the BeSt study): a randomized, controlled trial. Arthritis Rheum. 52(11), 3381-3390 (2005).
19. Wessels JA, de Vries-Bouwstra JK, Heijmans BT et al.: Effcacy and toxicity of methotrexate in early rheumatoid arthritis are associated with single-nucleotide polymorphisms in genes coding for folate pathway enzymes. Arthritis Rheum. 54(4), 1087-1095 (2006).
20. van der Heijde DM, van 't Hof M, van Riel PL, van de Putte LB: Development of a disease activity score based on judgment in clinical practice by rheumatologists. J. Rheumatol. 20(3), 579-581 (1993).
21. van Gestel AM, Prevoo ML, van 't Hof MA, van Rijswijk MH, van de Putte LB, van Riel PL: Development and validation of the European League Against Rheumatism response criteria for rheumatoid arthritis. Comparison with the preliminary American College of Rheumatology and the World Health Organization/International League Against Rheumatism Criteria. Arthritis Rheum. 39(1), 34-40 (1996).
22. Ritchie DM, Boyle JA, McInnes JM et al.: Clinical studies with an articular index for the assessment of joint tenderness in patients with rheumatoid arthritis. QJM 37(147), 393-406 (1968).
23. Goto Y, Yue L, Yokoi A et al.: A novel single-nucleotide polymorphism in the 3́-untranslated region of the human dihydrofolate reductase gene with enhanced expression. Clin. Cancer Res. 7(7), 1952-1956 (2001).
24. Mishra PJ, Humeniuk R, Mishra PJ, Longo-Sorbello GS, Banerjee D, Bertino JR: A miR-24 microRNA binding-site polymorphism in dihydrofolate reductase gene leads to methotrexate resistance. Proc. Natl Acad. Sci. USA 104(33), 13513-13518 (2007).
25. Pawlik A, Baskiewicz-Masiuk M, Machalinski B, Kurzawski M, Gawronska-Szklarz B: Involvement of C3435T and G2677T multidrug resistance gene polymorphisms in release of cytokines from peripheral blood mononuclear cells treated with methotrexate and dexamethasone. Eur. J. Pharmacol. 528(1-3), 27-36 (2005).
26. Wang J, Zeevi A, Webber S et al.: A novel variant L263F in human inosine 5́-monophosphate dehydrogenase 2 is associated with diminished enzyme activity. Pharmacogenet. Genomics 17(4), 283-290 (2007).
27. Rizzo R, Rubini M, Govoni M et al.: HLA-G 14-bp polymorphism regulates the methotrexate response in rheumatoid arthritis. Pharmacogenet. Genomics 16(9), 615-623 (2006).
28. von Ahsen N, Oellerich M, Armstrong VW: Characterization of the inosine triphosphatase (ITPA) gene: haplotype structure, haplotype-phenotype correlation and promoter function. Ther. Drug Monit. 30(1), 16-22 (2008).
29. Bohanec Grabar P, Logar D, Lestan B, Dolzan V: Genetic determinants of methotrexate toxicity in rheumatoid arthritis patients: a study of polymorphisms affecting methotrexate transport and folate metabolism. Eur. J. Clin. Pharmacol. 64(11), 1057-1068 (2008).
30. Drozdzik M, Rudas T, Pawlik A et al.: The effect of 3435C>T MDR1 gene polymorphism on rheumatoid arthritis treatment with disease-modifying antirheumatic drugs. Eur. J. Clin. Pharmacol. 62(11), 933-937 (2006).
31. Kuuliala K, Orpana A, Leirisalo-Repo M, et al.: Polymorphism at position +896 of the Toll-like receptor 4 gene interferes with rapid response to treatment in rheumatoid arthritis. Ann. Rheum. Dis. 65(9), 1241-1243 (2006).
32. Mattey DL, Nixon N, Dawes PT, Kerr J: Association of polymorphism in the transforming growth factor β1 gene with disease outcome and mortality in rheumatoid arthritis. Ann. Rheum. Dis. 64(8), 1190-1194 (2005).
33. Stamp LK, O'Donnell JL, Chapman PT et al.: Lack of association between HLA-G 14 bp insertion/deletion polymorphism and response to long-term therapy with methotrexate response in rheumatoid arthritis. Ann. Rheum. Dis. 68(1), 154-155 (2009).
34. Takatori R, Takahashi KA, Tokunaga D et al.: ABCB1 C3435T polymorphism infuences methotrexate sensitivity in rheumatoid arthritis patients. Clin. Exp. Rheumatol. 24(5), 546-554 (2006).
35. Sherry ST, Ward MH, Kholodov M et al.: dbSNP: the NCBI database of genetic variation. Nucleic Acids Res. 29(1), 308-311 (2001).
36. Kimchi-Sarfaty C, Oh JM, Kim IW et al.: A "silent" polymorphism in the MDR1 gene changes substrate specifcity. Science 315(5811), 525-528 (2007).
37. Drescher S, Schaeffeler E, Hitzl M et al.: MDR1 gene polymorphisms and disposition of the P-glycoprotein substrate fexofenadine. Br. J. Clin. Pharmacol. 53(5), 526-534 (2002).
38. Hoffmeyer S, Burk O, von RO et al.: Functional polymorphisms of the human multidrug-resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo. Proc. Natl Acad. Sci. USA 97(7), 3473-3478 (2000).
39. Wang D, Johnson AD, Papp AC, Kroetz DL, Sadee W: Multidrug resistance polypeptide 1 (MDR1, ABCB1) variant 3435CT affects mRNA stability. Pharmacogenet. Genomics 15(10), 693-704 (2005).
40. Hider SL, Owen A, Hartkoorn R et al.: Down regulation of multidrug resistance protein-1 expression in patients with early rheumatoid arthritis exposed to methotrexate as a frst disease-modifying antirheumatic drug. Ann. Rheum. Dis. 65(10), 1390-1393 (2006).
41. Norris MD, De GD, Haber M et al.: Involvement of MDR1 P-glycoprotein in multifactorial resistance to methotrexate. Int. J. Cancer 65(5), 613-619 (1996).
42. Ranganathan P, Culverhouse R, Marsh S et al.: Methotrexate (MTX) pathway gene polymorphisms and their effects on MTX toxicity in Caucasian and African American patients with rheumatoid arthritis. J. Rheumatol. 35(4), 572-579 (2008).
43. Baricordi OR, Stignani M, Melchiorri L, Rizzo R: HLA-G and infammatory diseases. Infamm. Allergy Drug Targets 7(2), 67-74 (2008).
44. Rudwaleit M, Yin Z, Siegert S et al.: Response to methotrexate in early rheumatoid arthritis is associated with a decrease of T cell derived tumour necrosis factor a, increase of interleukin 10, and predicted by the initial concentration of interleukin 4. Ann. Rheum. Dis. 59(4), 311-314 (2000).
45. Seitz M, Zwicker M, Wider B: Enhanced in vitro induced production of interleukin 10 by peripheral blood mononuclear cells in rheumatoid arthritis is associated with clinical response to methotrexate treatment. J. Rheumatol. 28(3), 496-501 (2001).
46. Hviid TV, Rizzo R, Christiansen OB, Melchiorri L, Lindhard A, Baricordi OR: HLA-G and IL-10 in serum in relation to HLA-G genotype and polymorphisms. Immunogenetics 56(3), 135-141 (2004).
47. Rizzo R, Hviid TV, Stignani M et al.: The HLA-G genotype is associated with IL-10 levels in activated PBMCs. Immunogenetics 57(3-4), 172-181 (2005).
48. Moreau P, Adrian-Cabestre F, Menier C et al.: IL-10 selectively induces HLA-G expression in human trophoblasts and monocytes. Int. Immunol. 11(5), 803-811 (1999).
49. Rousseau P, Le DM, Mouillot G, Marcou C, Carosella ED, Moreau P: The 14 bp deletion-insertion polymorphism in the 3́ UT region of the HLA-G gene infuences HLA-G mRNA stability. Hum. Immunol. 64(11), 1005-1010 (2003).
50. Cao H, Hegele RA: DNA polymorphisms in ITPA including basis of inosine triphosphatase defciency. J. Hum. Genet. 47(11), 620-622 (2002).
51. Takeda K, Kaisho T, Akira S: Toll-like receptors. Annu. Rev. Immunol. 21, 335-376 (2003).
52. Huang Q, Ma Y, Adebayo A, Pope RM: Increased macrophage activation mediated through Toll-like receptors in rheumatoid arthritis. Arthritis Rheum. 56(7), 2192-2201 (2007).
53. Radstake TR, Roelofs MF, Jenniskens YM et al.: Expression of Toll-like receptors 2 and 4 in rheumatoid synovial tissue and regulation by proinfammatory cytokines interleukin-12 and interleukin-18 via interferon-g. Arthritis Rheum. 50(12), 3856-3865 (2004).
54. Schroder NW, Schumann RR: Single nucleotide polymorphisms of Toll-like receptors and susceptibility to infectious disease. Lancet Infect. Dis. 5(3), 156-164 (2005).
55. Roelofs MF, Wenink MH, Toonen EJ et al.: The functional variant (Asp299gly) of Toll-like receptor 4 (TLR4) infuences TLR4-mediated cytokine production in rheumatoid arthritis. J. Rheumatol. 35(4), 558-561 (2008).
56. Radstake TR, Franke B, Hanssen S et al.: The Toll-like receptor 4 Asp299Gly functional variant is associated with decreased rheumatoid arthritis disease susceptibility but does not infuence disease severity and/or outcome. Arthritis Rheum. 50(3), 999-1001 (2004).
57. Sanchez E, Orozco G, Lopez-Nevot MA, Jimenez-Alonso J, Martin J: Polymorphisms of Toll-like receptor 2 and 4 genes in rheumatoid arthritis and systemic lupus erythematosus. Tissue Antigens 63(1), 54-57 (2004).
58. Crilly A, Hamilton J, Clark CJ, Jardine A, Madhok R: Analysis of transforming growth factor β1 gene polymorphisms in patients with systemic sclerosis. Ann. Rheum. Dis. 61(8), 678-681 (2002).
59. Taketazu F, Kato M, Gobl A et al.: Enhanced expression of transforming growth factor-β s and transforming growth factor-β type II receptor in the synovial tissues of patients with rheumatoid arthritis. Lab. Invest. 70(5), 620-630 (1994).
60. Arkwright PD, Laurie S, Super M et al.: TGF-β(1) genotype and accelerated decline in lung function of patients with cystic fbrosis. Thorax 55(6), 459-462 (2000).
61. Dunning AM, Ellis PD, McBride S et al.: A transforming growth factor β1 signal peptide variant increases secretion in vitro and is associated with increased incidence of invasive breast cancer. Cancer Res. 63(10), 2610-2615 (2003).
62. Hinke V, Seck T, Clanget C, Scheidt-Nave C, Ziegler R, Pfeilschifter J: Association of transforming growth factor-β1 (TGFβ1) T29-C gene polymorphism with bone mineral density (BMD), changes in BMD, and serum concentrations of TGF-β1 in a population-based sample of postmenopausal German women. Calcif. Tissue Int. 69(6), 315-320 (2001).
63. Yamada Y, Miyauchi A, Goto J et al.: Association of a polymorphism of the transforming growth factor-β1 gene with genetic susceptibility to osteoporosis in postmenopausal Japanese women. J. Bone Miner. Res. 13(10), 1569-1576 (1998).
64. Anderson JJ, Wells G, Verhoeven AC, Felson DT: Factors predicting response to treatment in rheumatoid arthritis: the importance of disease duration. Arthritis Rheum. 43(1), 22-29 (2000).
65. Hoekstra M, van Ede AE, Haagsma CJ et al.: Factors associated with toxicity, fnal dose, and effcacy of methotrexate in patients with rheumatoid arthritis. Ann. Rheum. Dis. 62(5), 423-426 (2003).
66. Little J, Bradley L, Bray MS et al.: Reporting, appraising, and integrating data on genotype prevalence and gene-disease associations. Am. J. Epidemiol. 156(4), 300-310 (2002).
67. Lohmueller KE, Pearce CL, Pike M, Lander ES, Hirschhorn JN: Meta-ana lysis of genetic association studies supports a contribution of common variants to susceptibility to common disease. Nat. Genet. 33(2), 177-182 (2003).